We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Unicycive Therapeutics Inc | NASDAQ:UNCY | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.009 | -1.37% | 0.646 | 0.646 | 0.6798 | 0.662 | 0.6386 | 0.66 | 217,493 | 00:57:34 |
From Jun 2023 to Jun 2024
Noble Capital Markets 19th Annual Emerging Growth Equity Conference (NobleCon)Presentation: Monday, December 4, 2023 at 3:30 pm ET Boca Raton, FLA high-definition video webcast of the presentation will be available the following day on the Unicycive website under the Investors section: Events and Presentations.
2023 Benchmark Discovery One-on-One Investor ConferenceDecember 7, 2023New York, NY
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn and YouTube.
Investor Contact:
ir@unicycive.com(650) 543-5470
SOURCE: Unicycive Therapeutics, Inc.
1 Year Unicycive Therapeutics Chart |
1 Month Unicycive Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
